Current and future therapies for age-related macular degeneration

Bibliography

• Evans J, Wormald R. Is the incidence of registrable age related macular degeneration increasing? Br J Ophthalmol 1996;80:9-14
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Klaver CC, Vingerling JR, et al. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003;18:845-54
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36
   PubMed Web of Science ®Google Scholar
• Davis MD, Gangnon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123:1484-98
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2002;109:1767-79
   PubMed Web of Science ®Google Scholar
• Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2007;114:92-8
   PubMed Web of Science ®Google Scholar
• Complications of Age-Related Macular Degeneration Prevention Trial Research Group (CAPT Research Group). Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 2006;1974-86
   PubMed Web of Science ®Google Scholar
• Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 2002;15:142-52
   PubMedGoogle Scholar
• Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization image-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. Arch Ophthalmol 1999;117:1329-45
   PubMed Web of Science ®Google Scholar
• Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. Arch Ophthalmol 2001;119:198-207
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Am J Ophthalmol 2001;131:541-60
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:407-18
   PubMed Web of Science ®Google Scholar
• Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials. Retina 2004;24:1-12
   PubMed Web of Science ®Google Scholar
• Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials. Am J Ophthalmol 2004;137:683-96
   PubMed Web of Science ®Google Scholar
• Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-67
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Adamis AP, Cunningham ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508-21
   PubMed Web of Science ®Google Scholar
• D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660-8
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64
   PubMedGoogle Scholar
• Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9
   PubMed Web of Science ®Google Scholar
• Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145:862-74
   Google Scholar
• Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-40
   PubMed Web of Science ®Google Scholar
• Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57
   PubMed Web of Science ®Google Scholar
• Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systemic review and economic evaluation. Health Technol Assess 2003;7:1-98
   Google Scholar
• Owen CG, Flethcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-7
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4
   PubMed Web of Science ®Google Scholar
• Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
   PubMed Web of Science ®Google Scholar
• Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006;113:1134
   PubMed Web of Science ®Google Scholar
• Ciardella AP, Donsoff IM, Guyer DR, et al. Antiangiogenesis agents. Ophthalmol Clin North Am 2002;15:453-8
   PubMedGoogle Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
   PubMed Web of Science ®Google Scholar
• Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-Fc fusion protein on experimental choroidal neovascularization [abstract]. Pharm Res 2009;26:204-10
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-7
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kogyo KK. Anti-human VEGF receptor Flt-1 monoclonal antibody. US6617160; 2003
   Google Scholar
• Leonard P, Scotney PD, Jabeen T, et al. Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment. J Mol Biol. 2008;384:1203-17
   Google Scholar
• Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707
   PubMed Web of Science ®Google Scholar
• Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008;216:29-37
   PubMed Web of Science ®Google Scholar
• Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44:4989-93
   PubMed Web of Science ®Google Scholar
• Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-9
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-30
   PubMed Web of Science ®Google Scholar
• Danis R, Criswell M, Orge F, et al. Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr Eye Res 2003;26:45-54
   PubMed Web of Science ®Google Scholar
• Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007;317:477
   PubMed Web of Science ®Google Scholar
• Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8:1343-6
   PubMed Web of Science ®Google Scholar
• Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009;16:10-6
   PubMed Web of Science ®Google Scholar
• Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002;8:718-24
   PubMed Web of Science ®Google Scholar
• Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-33
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-92
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene 2003;22:6537-48
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 2002;160:1683-93
   PubMed Web of Science ®Google Scholar
• Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204:1-10
   PubMed Web of Science ®Google Scholar
• Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999;40:182-9
   PubMed Web of Science ®Google Scholar
• Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcriptionby hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13
   PubMed Web of Science ®Google Scholar
• Wang B, Li H, Yan H, et al. Genistein inhibited hypoxia-inducible factor-1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods Find Exp Clin Pharmacol 2005;27:179-84
   PubMed Web of Science ®Google Scholar
• Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-21
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71
   PubMed Web of Science ®Google Scholar
• Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996;93:9764-9
   PubMed Web of Science ®Google Scholar
• Mikecz K. Vitaxin applied molecular evolution. Curr Opin Investig Drugs 2000;1:199-203
   PubMedGoogle Scholar
• Morgunova E, Tuuttila A, Bergmann U, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999;284:1667-70
   PubMed Web of Science ®Google Scholar
• Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8
   PubMed Web of Science ®Google Scholar
• Steen B, Sejersen S, Berglin L, et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998;39:2194-200
   PubMed Web of Science ®Google Scholar
• Lambert V, Munaut C, Jost M, et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol 2002;161:1247-53
   PubMed Web of Science ®Google Scholar
• Griffioen AW. AG-3340 (Agouron Pharmaceuticals Inc). IDrugs 2000;3:336-45
   PubMedGoogle Scholar
• Takahashi T, Nakamura T, Hayashi A, et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol 2000;130:774-81
   PubMed Web of Science ®Google Scholar
• Das A, McLamore A, Song W, et al. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999;117:498-503
   PubMed Web of Science ®Google Scholar
• Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001;17:295-304
   PubMed Web of Science ®Google Scholar
• Griffioen AW. AG-3340 (Agouron Pharmaceuticals Inc). IDrugs 2000;3:336-45
   PubMedGoogle Scholar
• Ando A, Yang A, Nambu H, et al. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol 2002;62:539-44
   PubMed Web of Science ®Google Scholar
• Ando A, Yang A, Mori K, et al. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol 2002;191:116-24
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28
   PubMed Web of Science ®Google Scholar
• Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003;22:6549-56
   PubMed Web of Science ®Google Scholar
• Sima J, Zhang SX, Shao C, et al. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 2004;564:19-23
   PubMed Web of Science ®Google Scholar
• Lai CC, Wu WC, Chen SL, et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001;42:2401-7
   PubMed Web of Science ®Google Scholar
• Raisler BJ, Berns KI, Grant MB, et al. Adeno-associated virus type-2 expression of pigmented pithelium-derived factor or kringles 1–3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002;99:8909-14
   PubMed Web of Science ®Google Scholar
• O'reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85
   PubMed Web of Science ®Google Scholar
• Marneros AG, Olsen BR. Physiological role of collagen XVIII and endostatin. FASEB J 2005;19:716-28
   PubMed Web of Science ®Google Scholar
• Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001;159:313-20
   PubMed Web of Science ®Google Scholar
• Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8
   PubMed Web of Science ®Google Scholar
• Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001;188:253-63
   PubMed Web of Science ®Google Scholar
• Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002;43:2428-34
   PubMed Web of Science ®Google Scholar
• Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol: an open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12:2029-32
   PubMedGoogle Scholar
• Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76
   PubMed Web of Science ®Google Scholar
• Stahl A, Paschek L, Martin G, et al. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 2008;582:3097-102
   PubMed Web of Science ®Google Scholar
• D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exsudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23
   PubMed Web of Science ®Google Scholar
• Available form: www.clinicaltrials.gov ID NCT00333216
   Google Scholar
• Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595-606
   PubMed Web of Science ®Google Scholar
• Radu RA, Mata NL, Nusinowitz S, et al. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci USA 2003;100:4742-7
   PubMed Web of Science ®Google Scholar
• Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102:20:7227-32
   PubMed Web of Science ®Google Scholar
• Mousa E, Dier T, Kannanayakal G. Patil. Anti-angiogenesis efficacy of the novel NF-kB and oxidative stress inhibitor, OT-551. Invest Ophthalmol Vis Sci 2008;49:E-Abstract 4590
   Google Scholar
• Piermarocchi S, Sartore M, Lo Giudice G, et al. Combination of photodynamic therapy and intraocular triamcinolone for exsudative age-related macular degeneration and long-term chorioretinal macular atrophy. Arch Ophthalmol 2008;126:1367-74
   PubMed Web of Science ®Google Scholar
• Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2005;16:R174-82
   Web of Science ®Google Scholar
• Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115:1019-25
   PubMed Web of Science ®Google Scholar